Stockreport

Artelo Biosciences Reports First Quarter 2022 Financial Results And Provides Business Update [TheStreet.com]

Artelo Biosciences, Inc.  (ARTL) 
US:NASDAQ Investor Relations: artelobio.com/investors
PDF $23.5 Million in Cash and Investments as of March 31, 2022, Expected to Support Completion of the CAReS Trial and Operations Into Second Half of 2023 Results of Phase 1 [Read more]